Novartis

A close-up of an associate controlling drug production at an AAA facility.

Turning the power of nuclear technology into a medical force

Advanced Accelerators Applications is working on marrying targeted drug design with nuclear medicine technology to develop drugs that can recognize and treat diseases.

Oncology research uncovers new insights about tumors.

Can data from a heart disease trial lead to a potential cancer treatment?

Novartis researchers are learning how a novel approach to immunotherapy could help treat cancer.

Latest News

Nov 17, 2019

Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Nov 15, 2019

New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
Nov 15, 2019

Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
Nov 13, 2019

Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa

Media releases

Novartis on Twitter

Super-resolution techniques reveal tubulin proteins (purple) in a neuron.

Using Super-Resolution Microscopy To See Neurodegeneration

Novartis data scientists are using super-resolution microscopy to see neurodegeneration the moment it starts.

Nurses screening a baby for sickle cell disease in a hospital in Ghana

Novartis pursues many paths to tackle sickle cell disease

Learn more about what we are doing to find new treatments for sickle cell disease and to expand people’s access to care.

Novartis Home

At Novartis, we are reimagining medicine

Turning the power of nuclear technology into a medical force

Can data from a heart disease trial lead to a potential cancer treatment?

Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF

New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease

Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)

Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa

Using Super-Resolution Microscopy To See Neurodegeneration

Novartis pursues many paths to tackle sickle cell disease